Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Three-dimensional quantitative structure activity relationship analyses of substrates for CYP2B6

S Ekins1, G Bravi, B J Ring

  • 1Department of Drug Disposition, Eli Lilly and Co., Indianapolis, Indiana, USA.

The Journal of Pharmacology and Experimental Therapeutics
|December 23, 1998
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

PNEUMOBILIA VERSUS PORTAL VENOUS GAS IN BLUNT ABDOMINAL TRAUMA.

The Ulster medical journal·2019
Same author

Differences in the low-energy collision-activated dissociation of carboxylate anions from structurally similar prostaglandins: E2, F 2α, D 2, and DHKF 2α.

Journal of the American Society for Mass Spectrometry·2013
Same author

Cross-reactivity studies and predictive modeling of "Bath Salts" and other amphetamine-type stimulants with amphetamine screening immunoassays.

Clinical toxicology (Philadelphia, Pa.)·2013
Same author

Computational modeling to accelerate the identification of substrates and inhibitors for transporters that affect drug disposition.

Clinical pharmacology and therapeutics·2012
Same author

Identification of peptides derived from the human antimicrobial peptide LL-37 active against biofilms formed by Pseudomonas aeruginosa using a library of truncated fragments.

Antimicrobial agents and chemotherapy·2012
Same author

Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs.

The pharmacogenomics journal·2010

Two 3D-QSAR models were developed to understand CYP2B6 interactions with substrates, successfully predicting most substrate Km values and highlighting model strengths and limitations.

Area of Science:

  • Pharmacology
  • Computational Chemistry
  • Drug Metabolism

Background:

  • Cytochrome P450 2B6 (CYP2B6) is a key enzyme in drug metabolism.
  • Understanding CYP2B6-substrate interactions is crucial for predicting drug efficacy and toxicity.
  • Quantitative structure-activity relationship (QSAR) models can elucidate these interactions.

Purpose of the Study:

  • To construct and compare two distinct 3D-QSAR models for CYP2B6 substrates.
  • To evaluate the predictive performance of these models for substrate Km (apparent) values.
  • To identify key molecular descriptors influencing CYP2B6 substrate binding.

Main Methods:

  • Development of a pharmacophore model using Catalyst software with 16 CYP2B6 substrates.
  • Construction of a partial least-squares (PLS) model using molecular surface-weighted holistic invariant molecular (MS-WHIM) descriptors.

Related Experiment Videos

  • Validation and comparison of both models using a test set of diverse CYP2B6 substrates.

    • Main Results:

    • The Catalyst pharmacophore model identified common features: three hydrophobic regions and one hydrogen bond acceptor.
    • The PLS MS-WHIM model yielded a cross-validated q2 value of 0.607, with size, electrostatic potential, hydrogen bonding, and hydrophobicity as key descriptors.
    • Both models achieved satisfactory predictions for most test substrates, though with specific limitations for verapamil (PLS MS-WHIM) and lidocaine (Catalyst).

    Conclusions:

    • Both 3D-QSAR approaches provide valuable insights into CYP2B6 substrate interactions.
    • The models demonstrate varying strengths and weaknesses in predicting substrate affinity.
    • Further refinement of these QSAR models is warranted for improved predictive accuracy in drug development.